Supreme™-NSCLC is the first-of-its-kind, cloud-native AI-powered clinical decision support (CDS) system purpose-built for non-small cell lung cancer (NSCLC). Designed to fit seamlessly into clinical workflows, Supreme™ leverages a multi-modal AI engine that integrates both DNA and RNA data—alongside previously discarded or “noisy” genomic signals—to generate real-time, evidence-based treatment recommendations tailored to each patient’s tumor biology.

Unlike static platforms limited to DNA variant matching, Supreme™ dynamically interprets the molecular complexity of NSCLC through proprietary AI modules: MESiCA (mutational signatures), STAMP (RNA-based predictive modeling), and TVA (tumor variant analysis). This layered approach enables the identification of likely responders, resistance markers, and combination therapy opportunities—supporting oncologists at the point of care with highly actionable insights.

Supreme™-NSCLC is FDA-exempt under CDS guidelines, allowing for rapid iteration and continuous performance improvement. Deployed as a plug-and-play SaaS on Google Cloud (with on-premise options), it ensures effortless EHR and DSS integration across hospital systems and tumor boards.

Built on 7+ years of research and clinically validated by leading cancer centers, Supreme™ is already in use within multidisciplinary tumor boards to improve clinical confidence in treatment selection and streamline decision-making. It supports oncologists without replacing their judgment—offering full transparency into the biological rationale behind each recommendation.

Whether for standard of care alignment, off-label strategies, or identifying patients for clinical trials, Supreme™-NSCLC empowers oncology teams to move faster, smarter, and with more precision—unlocking deeper value from existing genomic data.

GenoCure.AI combines next-gen genomics with powerful AI to guide smarter, personalized cancer treatments that improve lives.

Supreme™-NSCLC seamlessly augments EHR systems by delivering AI-powered clinical intelligence that standard EHRs cannot. While EHRs primarily store and display patient data, Supreme™ analyzes DNA, RNA, and noisy genomic signals to provide real-time, personalized treatment recommendations for NSCLC. Unlike basic rule-based alerts in EHRs, Supreme™ offers deep, predictive decision support—identifying drug resistance, therapy combinations, and response likelihoods. It integrates effortlessly via FHIR, CDS Hooks, and SMART-on-FHIR, enabling plug-and-play deployment within tumor boards and clinical workflows. As an FDA-exempt CDS platform, it evolves continuously, unlocking actionable insights that transform static genomic data into precise, timely clinical decisions.

Supreme™-NSCLC is a category-defining product that sets a new standard in AI-driven precision oncology. Unlike competitors relying on static models or single-omic analysis, Supreme™ integrates DNA, RNA, and “noisy” genomic signals using proprietary MESiCA, STAMP, and TVA technologies. Its proactive, self-evolving AI delivers real-time treatment recommendations with unmatched predictive accuracy. Cloud-native and FDA-exempt, Supreme™ enables rapid deployment, continuous updates, and seamless EHR integration—far outpacing slower, batch-based platforms. With pan-cancer scalability, minimal data requirements, and proven clinical impact, Supreme™ uniquely empowers oncologists with transparent, actionable insights—positioning it as the most advanced and scalable clinical decision support system in oncology today.